AveX­is shares spike on more pos­i­tive da­ta for SMA gene ther­a­py; Bio­gen stock tanks on fresh skep­ti­cism

→ AveX­is $AVXS says that 12 of the 12 in­fants suf­fer­ing from spinal mus­cu­lar at­ro­phy (SMA) who were treat­ed with AVXS-101 reached 13.6 months of age event free. And 9 of 9 reached 20 months event free. The com­pa­ny says that on­ly about one in four in­fants reach­es 13.6 months with­out an event. The biotech is push­ing ahead with a small piv­otal tri­al of a gene ther­a­py that is at­tract­ing a grow­ing amount of at­ten­tion. Their stock spiked 15% on the da­ta.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.